依帕司他联合和血明目片治疗糖尿病视网膜病变的临床研究  

A clinical study on the treatment of diabetic retinopathy with epalrestat and hexuemingmu tablets

作　　者：余明星 YU Mingxing(People's Hospital of Xinfeng County in Ganzhou,Ganzhou 341600,China)

机构地区：[1]信丰县人民医院

出　　处：《临床医药实践》2019年第8期573-576,共4页Proceeding of Clinical Medicine

基　　金：赣州市指导性科技计划项目(项目编号:GZ2018ZSF529)

摘　　要：目的:评价依帕司他联合和血明目片联合治疗糖尿病视网膜病变的疗效和安全性。方法:将60例早期糖尿病视网膜病变患者随机分为对照组和观察组。对照组给予依帕司他治疗,观察组给予依帕司他联合和血明目片联合治疗,比较两组患者治疗前后的氧化应激指标、炎症因子水平、总有效率、不良反应发生情况。结果:治疗前两组的血清超氧化物歧化酶(SOD)、丙二醛(MDA)、三醋酸纤维素(TAC)、超敏-C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)比较,差异均无统计学意义(P>0.05)。治疗后观察组的血清SOD、TAC水平高于对照组(P<0.05),MDA、hs-CRP、TL-6水平低于对照组(P<0.05),治疗总有效率高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:依帕司他联合和血明目片治疗糖尿病视网膜病变,疗效确切,不良反应少,安全性较高。Objective:To evaluate the efficacy and safety of the combined application of epastar and hexuemingmu tablets in the treatment of diabetic retinopathy.Methods:All 60 patients with early diabetic retinopathy were randomly divided into control group and observation group and control group according to palmer division.The control group was given epalrestat.The observation group was given epalrestat combined with hexuemingmu tablets.Results:The observation groups before treatment the serum superoxide dismutase(SOD),malondialdehyde(MDA),cellulose acetate(TAC),hypersensitive C-reactive protein(hs-CRP) and interleukin-6(IL-6) test results compared with the control group had no obvious difference ( P >0.05),after treatment of serum SOD,the TAC level higher than control group ( P <0.05),MDA,hs-CRP,TL-6 level was lower than those of control group( P <0.05),the total effective rate is relatively high in the control group( P <0.05),the incidence of adverse reactions compared with control group no significant difference ( P >0.05).Conclusion:The combined application of epastar and hemmingmu tablets in the treatment of diabetic retinopathy has definite curative effect,less adverse reactions and higher safety.

关 键 词：糖尿病视网膜病变 依帕司他 和血明目片 氧化应激指标 炎症因子 

分 类 号：R587.1[医药卫生—内分泌]